|
POLR3E expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.06970046340894E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.04539999989939E-08 |
| Normal-vs-Stage2 |
1.160480E-03 |
| Normal-vs-Stage3 |
5.53009971149265E-10 |
| Normal-vs-Stage4 |
3.0615000534695E-09 |
| Stage1-vs-Stage2 |
3.451000E-01 |
| Stage1-vs-Stage3 |
2.972200E-02 |
| Stage1-vs-Stage4 |
1.415890E-02 |
| Stage2-vs-Stage3 |
2.564000E-02 |
| Stage2-vs-Stage4 |
1.610070E-02 |
| Stage3-vs-Stage4 |
6.826200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.75829947560658E-10 |
| Normal-vs-AfricanAmerican |
8.779000E-04 |
| Normal-vs-Asian |
4.79740000003392E-06 |
| Caucasian-vs-AfricanAmerican |
7.846600E-01 |
| Caucasian-vs-Asian |
9.816200E-01 |
| AfricanAmerican-vs-Asian |
8.088600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.55410000424183E-08 |
| Normal-vs-Female |
3.4429004092118E-10 |
| Male-vs-Female |
6.811600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.40639999225112E-09 |
| Normal-vs-Age(41-60Yrs) |
1.22390000356631E-08 |
| Normal-vs-Age(61-80Yrs) |
9.4682999995932E-08 |
| Normal-vs-Age(81-100Yrs) |
4.503400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.506800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.058200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.977000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.215200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.001400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.127800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.519900E-03 |
| Classical-VS-Follicular |
6.393400E-01 |
| Classical-VS-Other |
4.342600E-01 |
| Classical-VS-Normal |
4.31340000051073E-07 |
| Tall-VS-Follicular |
4.143300E-03 |
| Tall-VS-Other |
5.350400E-01 |
| Tall-VS-Normal |
7.43090033950011E-10 |
| Follicular-VS-Other |
4.570800E-01 |
| Follicular-VS-Normal |
7.89330000000588E-05 |
| Other-VS-Normal |
8.697800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.57700000227956E-08 |
| Normal-vs-N1 |
2.10830000013651E-07 |
| N0-vs-N1 |
1.467580E-01 |
|
|
